💼 Business 12h ago

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial

CNBC Business
CNBC business news
View Channel →
Source ↗ 👁 0 💬 0
Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a milestone for gene editing.

Comments (0)

Sign in to join the discussion

More Like This

Want the lowest mortgage rate you can get? Credit-scoring changes mean home buyers need a new strategy.
MarketWatch.com - Top Stories · 10h ago
Itron earnings up next: Can smart meter maker ease volume concerns?
All News · 10h ago
Boeing completes first test flight of operational MQ-25A Stingray
All News · 10h ago
Asbury Automotive earnings on deck amid transformation test
All News · 10h ago
Zuckerberg is following Musk’s lead with this ‘transformative step’ in outer space
MarketWatch.com - Top Stories · 10h ago
Sogefi Q1 2026 slides: margins expand amid revenue pressure
All News · 10h ago